Omnix Medical
Resistance is not an option.
Jerusalem, Israel · Founded 2015 · $33.5M raised
- Headquarters
- Jerusalem
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- omnixmedical.com
- Total Funding
- $33.5M
- Last Round
- $25.0M Series COct 2025
- Rounds
- 2
About
Omnix Medical is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Jerusalem, Israel, dedicated to developing novel antibiotic agents against drug-resistant bacterial infections. The company's lead compound, OMN6, is a first-in-class antimicrobial peptide engineered for stability and selectivity, currently in Phase II clinical trials targeting sepsis and hospital-acquired infections. Omnix has raised over $33 million in funding from investors including Harel Insurance & Finance and the European Innovation Council Fund, and has received EU Horizon 2020 grants.
Summary
Omnix Medical is a Biotech company based in Jerusalem, Israel, founded in 2015. It has raised $33.5M in total across 2 rounds, most recently a $25.0M Series C round in Oct 2025. Investors include Entrée Capital, Tal Ventures and Harel Insurance & Finance.
Tech & App Stack
5 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Oct 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company